Brief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
19/10/2026 12:37
BRIEF-Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer Oct 19 (Reuters) - Marker Therapeutics Inc MRKR.O:
MARKER THERAPEUTICS AWARDED $2.6 MILLION FDA ORPHAN PRODUCTS DEVELOPMENT GRANT TO ADVANCE MT-601 IN PANCREATIC CANCER
MARKER THERAPEUTICS - FUNDING TO SUPPORT PHASE 1 STUDY OF MT-601 IN PANCREATIC CANCER
Source text: ID:nGNXDX7hV
Further company coverage: MRKR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79